14 completed, 11 unknown, 5 recruiting, 3 not yet recruiting. 38 Phase 2, 17 Phase 1, 3 Phase 3.
Follow Safety: new trials by email Literature Review of Safety trials Research Report on Safety
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy of iPSC-Derived Motor Neuron Cells (XS228) in Subacute Spinal Cord Injury: A Phase II Randomized Controlled Trial Allogeneic Human Induced Pluripotent Stem Cell (iPSC)-Derived Motor Neuron Progenitor Cells, Placebo - Spinal Cord Injury, Safety | Phase 2 | Not yet recruiting | XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. | 60 | 2028-05-25 | 2025-11-25 |
| To Evaluate the Safety and Efficacy of Hemay5394 in Patients With Mild to Moderate Atopic Dermatitis Hemay5394 group, Control group - Safety, Efficiency | Phase 2 | Not yet recruiting | Hemay Pharmaceutical PTY. LTD. | 90 | 2026-11-01 | 2026-10-16 |
| Phase 1/2 Clinical Study of HY07121 for Injection (Subcutaneous) in Patients With Advanced Solid Tumors Test Product HY07121 for Injection (Subcutaneous) - Safety, Tolerability | Phase 1 / Phase 2 | Not yet recruiting | Sichuan Huiyu Pharmaceutical Co., Ltd | 254 | 2026-09-08 | 2026-08-27 |
| Safety and Tolerability of IRL757 in Participants With Parkinson's Disease and Apathy IRL757, Placebo - PARKINSON DISEASE (Disorder), Apathy | Phase 1 / Phase 2 | Recruiting | Integrative Research Laboratories AB | 75 | 2026-02-18 | 2026-09-03 |
| Long-Term PEA Safety Study Palmitoylethanolamide (PEA), Placebo - Healthy, Safety | Phase 2 | Active not recruiting | RDC Clinical Pty Ltd | 200 | 2025-01-22 | 2026-09-09 |
| Phase 1/2 Clinical Study of HY07121 Powder for Solution for Infusion in Patients With Advanced Solid Tumors Test Product HY07121 - Safety, Tolerability | Phase 1 / Phase 2 | Recruiting | Sichuan Huiyu Pharmaceutical Co., Ltd | 258 | 2024-10-24 | 2026-10-13 |
| A Phase I/II Clinical Study to Evaluate the Safety and Efficacy of Oral Teslanbaicin in Patients With Radiation Proctitis A Phase I/II Clinical Study to Evaluate the Safety and Efficacy of Oral Tesilanbaiju in Patients with Radiation Proctitis, Teslanbai oral therapy - Safety | Phase 1 / Phase 2 | Enrolling by invitation | The First Affiliated Hospital of Xinxiang Medical College | 29 | 2024-10-15 | 2025-05-15 |
| Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS Mutation Test product: HYP-2090PTSA - Safety, Tolerability | Phase 1 / Phase 2 | Recruiting | Sichuan Huiyu Pharmaceutical Co., Ltd | 257 | 2024-02-04 | 2026-01-29 |
| Efficacy and Safety of AK104 Combined With Chemotherapy and Cetuximab or Bevacizumab AK104 and cetuximab or bevacizumab and FOLFIRI - Safety | Phase 2 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 40 | 2024-01-03 | 2025-11-28 |
| Radiotherapy Plus Anlotinib in LA-NSCLC Intolerable to cCRT Anlotinib - Locally Advanced Non-Small Cell Lung Cancer, Thoracic Radiotherapy | Phase 2 | Completed | JIANYANG WANG | 44 | 2024-01-01 | 2026-10-07 |
| A Study of GC101 TIL in Advanced Melanoma (BZ) GC101 TIL - Tumor Infiltrating Lymphocytes, Safety | Phase 1 / Phase 2 | Completed | Shanghai Juncell Therapeutics | 18 | 2023-11-08 | 2025-12-23 |
| Tirelizumab Combined With Chemotherapy in the Treatment of HER-2 Negative Locally Advanced Gastric Cancer Tirolizumab+SOX/XELOX, SOX/XELOX - Locally Advanced Gastric Carcinoma, HER2 Negative | Phase 2 | Unknown | Lin Chen | 80 | 2023-10-01 | 2024-02-29 |
| Curcumin and Retinal Study Low curcumin group, High curcumin group - Bioavailability, Gut Microbiome | Phase 1 / Phase 2 | Recruiting | Texas Tech University Health Sciences Center | 60 | 2023-08-21 | 2026-01-13 |
| FCN-338 in Combination With Azacitidine or Chemotherapy in Myeloid Neoplasms FCN-338 + Azacitidine, FCN-338 + erythromycin+ Ara-C - Safety, Antitumor Activity | Phase 2 | Active not recruiting | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 47 | 2023-08-16 | 2025-03-05 |
| Stereotactic Body Radiotherapy Combined With Cadonilimab for Advanced Refractory Malignant Solid Tumors Cadonilimab, Stereotactic body radiotherapy - Advanced Solid Tumor, Stereotactic Body Radiotherapy | Phase 1 / Phase 2 | Unknown | Peking University Third Hospital | 60 | 2023-06-21 | 2023-06-23 |
| A Phase II/III Study to Evaluate the Immunogenicity and Safety and Efficacy of SWIM816 Vaccines for SARS-CoV-2 Phase II:SWIM816;SARS-Cov-2;, Phase II:SW-BIC-213;SARS-Cov-2;, PhaseIII:SWIM816;SARS-Cov-2; - Immunogenicity, Safety | Phase 2 / Phase 3 | Unknown | Stemirna Therapeutics | 800 | 2023-06-20 | 2023-06-20 |
| Venetoclax Plus IM2 Regimen for Relapsed and Refractory T Lymphoblastic Lymphoma/Leukemia BCL2 Inhibitor plus IM2 regimen - T-lymphoblastic Lymphoma, Relapsed Disease | Phase 2 | Unknown | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 30 | 2023-01-10 | 2023-06-28 |
| Effect of Diuretics Withdrawal in Chronic Heart Failure With Reduced Ejection Fraction Diuretics withdrawal, Diuretics maintenance - Heart Failure, Electric Impedance | Phase 2 | Completed | Maimónides Biomedical Research Institute of Córdoba | 98 | 2022-12-19 | 2024-11-04 |
| A Phase Ic/IIb Study to Evaluate the Efficacy，Safety and Pharmacokinetics of HST in Patients With CHB Hepenofovir Fumarate Tablets - Efficacy, Safety | Phase 1 / Phase 2 | Unknown | Xi'an Xintong Pharmaceutical Research Co.,Ltd. | 48 | 2022-11-10 | 2023-11-08 |
| PD-L1 Inhibitor Rechallenge After PD-1 Immunotherapy for Patients With Solid Tumor Beyond Lung Cancer PD-L1 inhibitor - Efficacy, Safety | Phase 1 / Phase 2 | Unknown | The Affiliated Hospital of Qingdao University | 30 | 2022-04-01 | 2022-04-13 |
Showing 20 of 38. Sign in to see all of them.
COVID-19 (2) · Arthritis, Rheumatoid (1) · Asthma (1) · Carcinoma, Non-Small-Cell Lung (1) · Colorectal Neoplasms (1) · Diabetes Mellitus, Insulin-Dependent, 12 (1) · Diabetes Mellitus, Type 2 (1) · Drug-Related Side Effects and Adverse Reactions (1) · Dyspnea (1) · Edema (1) · Heart Failure (1) · Keloid (1) · Lethargy (1) · Leukemia (1) · Leukemia, Myeloid, Acute (1)
Neoplasms (5) · Respiratory Tract Diseases (5) · Lung Diseases (4) · Pathological Conditions, Signs and Symptoms (4) · Central Nervous System Diseases (3) · Immune System Diseases (3) · Infections (3) · Neoplasms by Histologic Type (3) · Neoplasms by Site (3) · Nervous System Diseases (3) · Skin and Connective Tissue Diseases (3) · Brain Diseases (2) · Cardiovascular Diseases (2) · Connective Tissue Diseases (2) · Coronaviridae Infections (2)
Control Groups (2) · 130-nm albumin-bound paclitaxel (1) · Adalimumab (1) · Adjuvants, Pharmaceutic (1) · Albuterol (1) · Azacitidine (1) · Bendamustine Hydrochloride (1) · Bevacizumab (1) · Brentuximab Vedotin (1) · Carboplatin (1) · Cetuximab (1) · Docetaxel (1) · Epirubicin (1) · Erythropoietin (1) · Immune Checkpoint Inhibitors (1)
Sichuan Huiyu Pharmaceutical Co., Ltd (3) · AstraZeneca (1) · Bangkok Metropolitan Administration Medical College and Vajira Hospital (1) · Bundang CHA Hospital (1) · Centre Antoine Lacassagne (1) · Cutia Therapeutics（Wuxi）Co.,Ltd (1) · Good Food Practice, Sweden (1) · Hao Long (1) · Hemay Pharmaceutical PTY. LTD. (1) · Huilan Zhang (1) · Institute for Developing Science and Health Initiatives, Bangladesh (1) · Integrative Research Laboratories AB (1) · JIANYANG WANG (1) · Jiangsu Province Centers for Disease Control and Prevention (1) · Lin Chen (1)
China (17) · Germany (4) · Australia (2) · Bulgaria (2) · France (2) · Spain (2) · Uganda (2) · United Kingdom (2) · Bangladesh (1) · Lithuania (1) · Mozambique (1) · Netherlands (1) · Poland (1) · South Korea (1) · Sweden (1)
Alberto Torres Zamudio, MD (1) · Andrea Ludwig-Sengpiel, Dr. (1) · Anne-Marie Kirsten, Dr. (1) · Anneliese Linnhoff, Dr. med. (1) · Christine Grigat, Dr. (1) · Dirk Skowasch, Prof. (1) · Dorte X Gram, PhD (1) · Helen McShane, Professor (1) · Hongqing Zhuang, M.D. (1) · Johan Olsson, PhD (1) · Jun Guo (1) · Jutta Beier, Dr. med. (1)
PMID 21791539, PMID 23352749, PMID 25176015, PMID 28390780, PMID 30121146, PMID 30741494, PMID 30777086, PMID 31424503, PMID 32171764, PMID 32673497, PMID 33538338, PMID 33736819, PMID 34447992, PMID 36028897, PMID 36525180, PMID 39858024, PMID 40037774, PMID 40693391, PMID 41456040, PMID 41499358, PMID 42644287, PMID 42648772
2014 (1), 2018 (1)